CureVac Financial Statements From 2010 to 2024

CVAC Stock  USD 2.77  0.11  4.14%   
CureVac NV financial statements provide useful quarterly and yearly information to potential CureVac NV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CureVac NV financial statements helps investors assess CureVac NV's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting CureVac NV's valuation are summarized below:
Gross Profit
-91.5 M
Market Capitalization
596.7 M
Enterprise Value Revenue
0.1017
Revenue
65.9 M
Earnings Share
0.49
We have found one hundred twenty available fundamental signals for CureVac NV, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of CureVac NV's prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of November 25, 2024, Market Cap is expected to decline to about 797.8 M. In addition to that, Enterprise Value is expected to decline to about 454.9 M

CureVac NV Total Revenue

55.62 Million

Check CureVac NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CureVac NV's main balance sheet or income statement drivers, such as Tax Provision of 70.3 K, Net Interest Income of 5.7 M or Interest Income of 13.6 M, as well as many indicators such as Price To Sales Ratio of 14.84, Dividend Yield of 0.0 or PTB Ratio of 1.54. CureVac financial statements analysis is a perfect complement when working with CureVac NV Valuation or Volatility modules.
  
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

CureVac NV Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets838.7 M788.2 M427.9 M
Slightly volatile
Other Current Liabilities70.9 M88 M37.5 M
Slightly volatile
Total Current Liabilities184.1 M186.4 M94.2 M
Slightly volatile
Other Liabilities198.2 M99.6 M108.6 M
Slightly volatile
Property Plant And Equipment Net171.9 M278.6 M98.2 M
Slightly volatile
Current Deferred Revenue56.8 M46.3 M27.5 M
Slightly volatile
Accounts Payable49.3 M46.4 M26 M
Slightly volatile
Cash565.5 M402.8 M254.8 M
Slightly volatile
Non Current Assets Total192.9 M309.9 M111 M
Slightly volatile
Other Assets0.951.05.2 M
Slightly volatile
Cash And Short Term Investments575.1 M402.8 M279.8 M
Slightly volatile
Net Receivables19.5 M17.1 M12 M
Slightly volatile
Common Stock Total Equity26.1 M24.9 M8.2 M
Slightly volatile
Common Stock Shares Outstanding200 M220.8 M179.9 M
Slightly volatile
Short Term Investments2.5 M2.7 M24.8 M
Slightly volatile
Liabilities And Stockholders Equity838.7 M788.2 M427.9 M
Slightly volatile
Non Current Liabilities Total150.8 M84.9 M120.4 M
Slightly volatile
Inventory23.6 M24.8 M11.7 M
Slightly volatile
Other Current Assets17.5 MM8.9 M
Slightly volatile
Total Liabilities391.5 M271.3 M218.4 M
Slightly volatile
Deferred Long Term Liabilities258.2 K271.8 K672.5 K
Slightly volatile
Net Invested Capital459.1 M516.9 M214.7 M
Slightly volatile
Property Plant And Equipment Gross186 M301.8 M101.6 M
Slightly volatile
Total Current Assets645.8 M478.4 M316.9 M
Slightly volatile
Accumulated Other Comprehensive Income1.4 B2.1 B858.4 M
Slightly volatile
Capital Stock17.6 M26.9 M7.9 M
Slightly volatile
Non Current Liabilities Other16.2 K17.1 K593.1 K
Slightly volatile
Net Working Capital461.7 M292 M222.6 M
Slightly volatile
Short Term Debt3.5 MM1.6 M
Slightly volatile
Intangible Assets13.7 M15.9 M9.2 M
Slightly volatile
Common Stock17.6 M26.9 M7.9 M
Slightly volatile
Property Plant Equipment242 M230.5 M93.3 M
Slightly volatile
Short and Long Term Debt Total35.5 M41.8 M64.7 M
Slightly volatile
Long Term Debt52 M58.5 M63.7 M
Slightly volatile

CureVac NV Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income13.6 M12.9 M4.1 M
Slightly volatile
Depreciation And Amortization20.3 M23.4 M10.8 M
Slightly volatile
Interest Expense2.4 M2.5 MM
Slightly volatile
Selling General Administrative66 M76 M39.3 M
Slightly volatile
Selling And Marketing Expenses820.9 K424 KM
Pretty Stable
Total Revenue55.6 M53.8 M30.8 M
Slightly volatile
Other Operating Expenses279.2 M328 M165.8 M
Slightly volatile
Research Development218.7 M115.7 M116.4 M
Slightly volatile
Cost Of Revenue111.2 M124.4 M57.3 M
Slightly volatile
Total Operating Expenses172.1 M211.8 M110.3 M
Slightly volatile
Reconciled Depreciation14.5 M17.8 M8.2 M
Slightly volatile

CureVac NV Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow510 M495.8 M272.6 M
Slightly volatile
Depreciation15.5 M23.4 M8.7 M
Slightly volatile
Capital Expenditures64.3 M55.2 M35.5 M
Slightly volatile
End Period Cash Flow565.5 M402.5 M254.7 M
Slightly volatile
Other Cashflows From Investing Activities2.9 M3.7 M2.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.8415.6212454
Slightly volatile
Days Sales Outstanding169116177
Slightly volatile
Capex To Depreciation3.262.36043.9264
Very volatile
EV To Sales8.468.9066450
Slightly volatile
Inventory Turnover3.795.01465.3548
Slightly volatile
Days Of Inventory On Hand13272.788189.3474
Slightly volatile
Payables Turnover2.822.68232.2591
Pretty Stable
Sales General And Administrative To Revenue1.561.41391.5172
Pretty Stable
Research And Ddevelopement To Revenue3.52.15273.2325
Very volatile
Capex To Revenue0.861.02681.0984
Pretty Stable
Cash Per Share2.581.82681.6492
Slightly volatile
Days Payables Outstanding214136191
Very volatile
Intangibles To Total Assets0.03420.0360.0411
Slightly volatile
Current Ratio2.562.56662.8346
Pretty Stable
Receivables Turnover5.643.14674.1958
Slightly volatile
Graham Number5.927.88984.0439
Slightly volatile
Capex Per Share0.260.25040.1912
Slightly volatile
Revenue Per Share0.220.24380.1664
Slightly volatile
Interest Debt Per Share0.01070.01130.0423
Pretty Stable
Debt To Assets0.40.450.4881
Slightly volatile
Operating Cycle302189266
Very volatile
Days Of Payables Outstanding214136191
Very volatile
Ebt Per Ebit1.10.94810.9928
Slightly volatile
Long Term Debt To Capitalization2.342.632.8677
Slightly volatile
Total Debt To Capitalization2.342.632.8677
Slightly volatile
Quick Ratio2.452.43352.7162
Pretty Stable
Net Income Per E B T0.81.00080.9869
Slightly volatile
Cash Ratio1.982.1611.5238
Slightly volatile
Days Of Inventory Outstanding13272.788189.3474
Slightly volatile
Days Of Sales Outstanding169116177
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.931.20611.1649
Slightly volatile
Fixed Asset Turnover0.360.19290.308
Pretty Stable
Debt Ratio0.40.450.4881
Slightly volatile
Price Sales Ratio14.8415.6212454
Slightly volatile
Asset Turnover0.09230.06820.0944
Slightly volatile

CureVac NV Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap797.8 M839.8 M6.9 B
Slightly volatile
Enterprise Value454.9 M478.8 M6.7 B
Slightly volatile

CureVac Fundamental Market Drivers

Forward Price Earnings5.2356
Cash And Short Term Investments402.8 M

CureVac Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
23rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CureVac NV Financial Statements

CureVac NV stakeholders use historical fundamental indicators, such as CureVac NV's revenue or net income, to determine how well the company is positioned to perform in the future. Although CureVac NV investors may analyze each financial statement separately, they are all interrelated. For example, changes in CureVac NV's assets and liabilities are reflected in the revenues and expenses on CureVac NV's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CureVac NV. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue46.3 M56.8 M
Total Revenue53.8 M55.6 M
Cost Of Revenue124.4 M111.2 M
Stock Based Compensation To Revenue 0.14  0.28 
Sales General And Administrative To Revenue 1.41  1.56 
Research And Ddevelopement To Revenue 2.15  3.50 
Capex To Revenue 1.03  0.86 
Revenue Per Share 0.24  0.22 
Ebit Per Revenue(5.10)(5.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.49
Revenue Per Share
0.294
Quarterly Revenue Growth
0.905
Return On Assets
(0.25)
Return On Equity
(0.54)
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.